EA5163 aka S1709 aka INSIGNA – A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis
Physician and Research Staff Educational Materials:
These materials are intended for promotional use among health care professionals and are NOT intended for use as patient educational materials.
- Pocket Reference Card: trial schema, study objectives, and eligibility requirements on a pocket-sized card for easy reference when consulting with patients in the office or on rounds.
- Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study.
Information and Assistance from the National Cancer Institute:
- Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.